[Leish-l] RES: testing vaccinated dogs for immunopotentiation

Chang, Kwang-Poo KwangPoo.Chang at rosalindfranklin.edu
Wed Sep 28 12:19:40 BRT 2011


Christine Petersen published an article about transplacental
transmission of L infantum in the USA canine leishmaniasis. I just
wonder about the implication of this finding in considering vaccination
against the disease transmitted this way ?

 

KP

 

________________________________

From: leish-l-bounces at lineu.icb.usp.br
[mailto:leish-l-bounces at lineu.icb.usp.br] On Behalf Of TECSA - Luiz
Ristow
Sent: Wednesday, September 28, 2011 9:08 AM
To: 'John David'
Cc: leish-l at lineu.icb.usp.br
Subject: [Leish-l] RES: testing vaccinated dogs for immunopotentiation

 

Hi !

 

There are these papers about

These need a very critical reading to discuss

This discussion with all about the matter and these papers is very
welcome! (at least for me!)

Regards for all

Luiz Ristow

 

 

 

De: leish-l-bounces at lineu.icb.usp.br
[mailto:leish-l-bounces at lineu.icb.usp.br] Em nome de John David
Enviada em: segunda-feira, 26 de setembro de 2011 18:44
Para: Dr GR Rajasekariah
Cc: leish-l at lineu.icb.usp.br; Carlos Gouvea; hubert mazure;
smithyman at cellabs.com.au
Assunto: Re: [Leish-l] testing vaccinated dogs for immunopotentiation

 

I think that for any vaccine developed to protect dogs against VL, but
which is also meant to prevent transmission of VL to humans, the
developers should show that after the vaccinated dog has been challenged
with Leishmania, it does not transmit Leishmania to sand flies.

John R David, M.D.

Richard Pearson Strong Professor Emeritus

Department of Immunology and Infectious Diseases

Harvard School of Public Health

Professor of Medicine, Harvard Medical School

300 W. 23rd Street, Apt. 13K

New York, NY, 10011

Tel: 212 414 8646

Email: jdavid at hsph.harvard.edu

 

 

On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:

 

Hello EveryOne,
I am responding to the topic on European VL Dog vaccine.
It is a great challenge in devising a protective vaccine  against
visceral leishmaniasis in dogs. This point equally applies the same
challenge for human situation.
Because Th-2 response is so dominant during VL infection, modulating
Th-2 into Th-1 response is a big challenge to immunologists.

Key points lies in the presentation of appropriate antigen in
appropriate dose to stimulate the  Th-1 dependent protective immune
response.
I understand several vaccines are in the market and real efficacy of
these vaccines will come out once introduced to field conditions.

I just wanted to inform you that we have a suitable antibody kit  for
testing the immunopotentiation in dogs following vaccination of dogs.
Our assay is based on the released promastigote antigens.
It is a highly sensitive assay.
Currently we supply reagents for  determination of total IgG antibodies
in serum.
If any particular group is interested then we are able to provide
appropriate reagent for detection of specific IgG2 and other isotype
specific antibody detection.
Because our antibody detection ELISA is based on the exo-antigens such
an ELISA would be of exceptional type for measuring antibody response in
vaccinated animals.
Highly suitable for diagnosing dogs responded to vaccines.

Recently I came to know that some of  commercial kits were found to be
not useful for detecting seroconversion in dogs vaccinated with FML
vaccine (Leish-Immune) in Brazil.
Because we use released antigens in our kit, any such problems will
overcome if they use Canine Leish IgG CELISA (Manufacturer Cellabs Pty
Ltd Brookvale NSW Australia email sales at cellabs.com.au).
If any one is interested to know more about our antibody detection ELISA
based on exo-antigens please contact us.

This is for your kind information.

Dr GR Rajasekariah
Sydney
Australia
raj at cellabs.com.au






----- Original Message ----- From: <leish-l-request at lineu.icb.usp.br>
To: <leish-l at lineu.icb.usp.br>
Sent: Wednesday, August 10, 2011 5:18 PM
Subject: Leish-l Digest, Vol 44, Issue 3




Send Leish-l mailing list submissions to

	leish-l at lineu.icb.usp.br

	 

	To subscribe or unsubscribe via the World Wide Web, visit

	http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l

	or, via email, send a message with subject or body 'help' to

	leish-l-request at lineu.icb.usp.br

	 

	You can reach the person managing the list at

	leish-l-owner at lineu.icb.usp.br

	 

	When replying, please edit your Subject line so it is more
specific

	than "Re: Contents of Leish-l digest..."

	 

	 

	Today's Topics:

	 

	 1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)

	 2. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)

	 3. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)

	 

	 

	
----------------------------------------------------------------------

	 

	Message: 1

	Date: Tue, 9 Aug 2011 15:18:44 +0000

	From: jeffrey shaw <jayusp at hotmail.com>

	Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:

	To: Leish-L <leish-l at lineu.icb.usp.br>

	Message-ID: <COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>

	Content-Type: text/plain; charset="windows-1252"

	 

	 

	CaniLeish?:

	  The European Commission granted a marketing authorisation
valid throughout the European Union, for CaniLeish to Virbac S.A. on
14/03/2011.

	 This vaccine, CaniLeish?, will initially be launched in
Portugal at the end of the first half of 2011. This will be followed
rapidly by launches in other countries in the endemic area: Spain,
France, Greece and Italy (not in chronological order). This roll-out
takes account of the geographical prevalence of the disease and the time
required to build vaccine production up to full capacity. The launch in
Northern European countries from where there is a flow of summer
visitors to the endemic area will be part of a second phase.

	  The basis of this vaccine are excreted proteins plus a saponin
adjuvant purified from Quil-A. Its efficacy was determined in a 2 year
open field trial.

	  The vaccine is given to dogs as three injections, three weeks
apart, under the skin. The first injection can be given from six months
of age, the second injection is given three weeks later and the third
three weeks from the second one. Afterward a single ?booster? should be
given every year to maintain protection.

	-------------- next part --------------

	An HTML attachment was scrubbed...

	URL:
<http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e
/attachment-0001.htm>

	 

	------------------------------

	 

	Message: 2

	Date: Wed, 10 Aug 2011 13:07:17 +0600

	From: Moazzem Hossain <directordcbd at gmail.com>

	Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network

	To: jeffrey shaw <jayusp at hotmail.com>, "Prof. Paul Kaye"

	<paul.kaye at york.ac.uk>

	Cc: "Prof. Dr. Moazzem Hossain"
<profdrmoazzemhossain at gmail.com>,

	Leish-L <leish-l at lineu.icb.usp.br>

	Message-ID:

	
<CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com>

	Content-Type: text/plain; charset=windows-1252

	 

	10 Aug 2011

	 

	Dear Professor Paul Kaye,

	 

	Thank you for your email. Please find attached our supportive
letter

	of interest for Leishmaniasis Pathology Network.

	Looking forward for your kind response.

	 

	Best regards.

	 

	 

	-- 

	*Prof. Dr. Moazzem Hossain *

	Ex - Director Disease Control

	Ministry of Health & Family Welfare

	Government of  Bangladesh

	*Mailing address*:

	Founder Chairman and Project Director

	Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)

	Room 4 - 5 (2nd Floor), Green Super Market, Green Road

	Dhaka -1205, Bangladesh.

	Phone:880-2-8115646 (O )

	        880-1715038551(Mobile)

	Email: directordcbd at gmail.com

	 

	 

	 

	 

	 

	 

	 

	 

	On 8/9/11, jeffrey shaw <jayusp at hotmail.com> wrote:

		 

		 

		 

		Date: Tue, 9 Aug 2011 11:58:52 +0100

		From: paul.kaye at york.ac.uk

		 

		Subject: Leishmaniasis Pathology Network

		 

		 

		 

		 

		 

		 

		 

		 

		 

		   Dear all,

		   Invitation to participate in a global pathology

		     network for

		     research and training in leishmaniasis
(LeishPathNet)

		   You may recall the Dormy House meeting in 2008

		     and some of

		     the plans we put forward?  Over

		     the past

		     couple years, I have also spoken more to a few of
you about one

		     idea that was

		     formulated at Dormy, namely of setting up a digital
pathology

		     network. I have

		     also had numerous discussions with the major
equipment

		     manufacturers to see if

		     any of them would be supportive of helping us to
develop such an

		     initiative.  There have

		     been two major

		     develoments recently.  First,

		     Carl Zeiss

		     is willing to work with us to set up an integrated
global digital

		     pathology

		     network (providing a significant financial and
technical

		     contribution) and

		     second, the Wellcome Trust is willing to review a
pre-proposal to

		     fund the

		     initiative through their new Biomedical Resources
Grant scheme

	
(http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/St
rategic-awards-and-initiatives/wtdv031727.htm)

		     .

		   I have attached an outline of the project that

		     I had sent to

		     the Trust for their initial views, which I think is
reasonably

		     self-explanatory.

		      They appeared very

		     enthusiastic!  The main

		     question now is whether enough of

		     you are still supportive? [ I will also be sending
this email to

		     others, but please feel free to circulate ]

		 

		 

		   I think the

		       project will be

		       challenging, but success could have a real impact
on the way we

		       conduct

		       business.  It should serve not only as a vehicle
to enhance

		       research in

		       leishmaniasis, but the model would be equally
applicable across

		       a broad range

		       of diseases and global challenges (with
leishmaniasis setting

		       the pace).

		   If we wish to

		       proceed, the requirements

		       are that we submit a pre-proposal to the Trust by
Oct 18th 2011.

		       This pre-proposal is short (4 sections of 350
words) and

		       requires

		       letters of support from the community.

		   If you are

		       supportive of the idea that

		       we try to take this forward (and there is plenty
of scope for

		       later iteration

		       of the detail), I would be grateful if you could
please provide

		       me with a

		       letter of support by September

		         12th

		         2011, indicating whether you would like to be a
network

		       partner if the bid

		       is successful.  You could

		       also be

		       supportive but not wish to become directly
involved at this

		       stage, and such

		       letters are equally valuable. Your letter might
also stress the

		       added value

		       that the network could provide, its importance
for research and

		       training and/or

		       for progressing the translational agenda.

		       It would also be an opportunity to indicate
whether your

		       group (or

		       institute, if multiple groups) would be
interested in bidding to

		       be one of the

		       initial ?designated laboratories?.

		   If there is

		       sufficient support to

		       proceed and if subsequently the pre-proposal is
successful (we

		       will know on 22nd

		       Nov), then I will need a few volunteers to help
finalise the

		       full proposal,

		       which will be due on Jan 26th 2012.

		       A funding decision will be made on May 26th

		       2012.

		   Best wishes

		       and of course I am happy to

		       discuss any points further (though I will be out
of the UK from

		       Aug 10 ?Sept

		       12)

		   Paul

		 

		 

		 

		 

		 

		 

		 

		   --

		Professor Paul Kaye, Ph.D., FRCPath.

		Deputy Dean (Research), Hull York Medical School, and

		Director, Centre for Immunology and Infection

		Department of Biology and Hull York Medical School

		University of York

		Wentworth Way

		York YO10 5YW

		United Kingdom

		 

		Tel:  +44 (0)1904 328840

		Fax:  +44 (0)1904 328844

		Email: paul.kaye at york.ac.uk
<mailto:paul.kaye at york.ac.uk>

		 

		Centre Administrator and PA: Elizabeth Greensted

		Tel:  01904 328845

		Email: liz.greensted at york.ac.uk
<mailto:liz.greensted at york.ac.uk>

		 

		Centre Email: cii at york.ac.uk <mailto:cii at york.ac.uk>

		 

		Centre website: http://www.york.ac.uk/cii

		 

		Times Higher Education University of the Year 2010

		 

		Email disclaimer:
http://www.york.ac.uk/docs/disclaimer/email.htm

		 

		 

	 

	 

	------------------------------

	 

	Message: 3

	Date: Wed, 10 Aug 2011 13:06:47 +0600

	From: Moazzem Hossain <directordcbd at gmail.com>

	Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network

	To: jeffrey shaw <jayusp at hotmail.com>, "Prof. Paul Kaye"

	<paul.kaye at york.ac.uk>

	Cc: "Prof. Dr. Moazzem Hossain"
<profdrmoazzemhossain at gmail.com>,

	Leish-L <leish-l at lineu.icb.usp.br>

	Message-ID:

	
<CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.com>

	Content-Type: text/plain; charset="windows-1252"

	 

	10 Aug 2011

	 

	Dear Professor Paul Kaye,

	 

	Thank you for your email. Please find attached our supportive
letter

	of interest for Leishmaniasis Pathology Network.

	Looking forward for your kind response.

	 

	Best regards.

	 

	 

	-- 

	*Prof. Dr. Moazzem Hossain *

	Ex - Director Disease Control

	Ministry of Health & Family Welfare

	Government of  Bangladesh

	*Mailing address*:

	Founder Chairman and Project Director

	Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)

	Room 4 - 5 (2nd Floor), Green Super Market, Green Road

	Dhaka -1205, Bangladesh.

	Phone:880-2-8115646 (O )

	        880-1715038551(Mobile)

	Email: directordcbd at gmail.com

	 

	 

	 

	 

	 

	 

	 

	 

	On 8/9/11, jeffrey shaw <jayusp at hotmail.com> wrote:

		 

		 

		 

		Date: Tue, 9 Aug 2011 11:58:52 +0100

		From: paul.kaye at york.ac.uk

		 

		Subject: Leishmaniasis Pathology Network

		 

		 

		 

		 

		 

		 

		 

		 

		 

		   Dear all,

		   Invitation to participate in a global pathology

		     network for

		     research and training in leishmaniasis
(LeishPathNet)

		   You may recall the Dormy House meeting in 2008

		     and some of

		     the plans we put forward?  Over

		     the past

		     couple years, I have also spoken more to a few of
you about one

		     idea that was

		     formulated at Dormy, namely of setting up a digital
pathology

		     network. I have

		     also had numerous discussions with the major
equipment

		     manufacturers to see if

		     any of them would be supportive of helping us to
develop such an

		     initiative.  There have

		     been two major

		     develoments recently.  First,

		     Carl Zeiss

		     is willing to work with us to set up an integrated
global digital

		     pathology

		     network (providing a significant financial and
technical

		     contribution) and

		     second, the Wellcome Trust is willing to review a
pre-proposal to

		     fund the

		     initiative through their new Biomedical Resources
Grant scheme

	
(http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/St
rategic-awards-and-initiatives/wtdv031727.htm)

		     .

		   I have attached an outline of the project that

		     I had sent to

		     the Trust for their initial views, which I think is
reasonably

		     self-explanatory.

		      They appeared very

		     enthusiastic!  The main

		     question now is whether enough of

		     you are still supportive? [ I will also be sending
this email to

		     others, but please feel free to circulate ]

		 

		 

		   I think the

		       project will be

		       challenging, but success could have a real impact
on the way we

		       conduct

		       business.  It should serve not only as a vehicle
to enhance

		       research in

		       leishmaniasis, but the model would be equally
applicable across

		       a broad range

		       of diseases and global challenges (with
leishmaniasis setting

		       the pace).

		   If we wish to

		       proceed, the requirements

		       are that we submit a pre-proposal to the Trust by
Oct 18th 2011.

		       This pre-proposal is short (4 sections of 350
words) and

		       requires

		       letters of support from the community.

		   If you are

		       supportive of the idea that

		       we try to take this forward (and there is plenty
of scope for

		       later iteration

		       of the detail), I would be grateful if you could
please provide

		       me with a

		       letter of support by September

		         12th

		         2011, indicating whether you would like to be a
network

		       partner if the bid

		       is successful.  You could

		       also be

		       supportive but not wish to become directly
involved at this

		       stage, and such

		       letters are equally valuable. Your letter might
also stress the

		       added value

		       that the network could provide, its importance
for research and

		       training and/or

		       for progressing the translational agenda.

		       It would also be an opportunity to indicate
whether your

		       group (or

		       institute, if multiple groups) would be
interested in bidding to

		       be one of the

		       initial ?designated laboratories?.

		   If there is

		       sufficient support to

		       proceed and if subsequently the pre-proposal is
successful (we

		       will know on 22nd

		       Nov), then I will need a few volunteers to help
finalise the

		       full proposal,

		       which will be due on Jan 26th 2012.

		       A funding decision will be made on May 26th

		       2012.

		   Best wishes

		       and of course I am happy to

		       discuss any points further (though I will be out
of the UK from

		       Aug 10 ?Sept

		       12)

		   Paul

		 

		 

		 

		 

		 

		 

		 

		   --

		Professor Paul Kaye, Ph.D., FRCPath.

		Deputy Dean (Research), Hull York Medical School, and

		Director, Centre for Immunology and Infection

		Department of Biology and Hull York Medical School

		University of York

		Wentworth Way

		York YO10 5YW

		United Kingdom

		 

		Tel:  +44 (0)1904 328840

		Fax:  +44 (0)1904 328844

		Email: paul.kaye at york.ac.uk
<mailto:paul.kaye at york.ac.uk>

		 

		Centre Administrator and PA: Elizabeth Greensted

		Tel:  01904 328845

		Email: liz.greensted at york.ac.uk
<mailto:liz.greensted at york.ac.uk>

		 

		Centre Email: cii at york.ac.uk <mailto:cii at york.ac.uk>

		 

		Centre website: http://www.york.ac.uk/cii

		 

		Times Higher Education University of the Year 2010

		 

		Email disclaimer:
http://www.york.ac.uk/docs/disclaimer/email.htm

		 

		 

	-------------- next part --------------

	A non-text attachment was scrubbed...

	Name: Letter Leish UK.doc

	Type: application/msword

	Size: 46080 bytes

	Desc: not available

	URL:
<http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a
/attachment.doc>

	 

	------------------------------

	 

	_______________________________________________

	Leish-l mailing list

	Leish-l at lineu.icb.usp.br

	http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l

	 

	 

	End of Leish-l Digest, Vol 44, Issue 3

	************************************** 






=======
Email scanned by PC Tools - No viruses or spyware found.
(Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)
http://www.pctools.com/
=======
_______________________________________________
Leish-l mailing list
Leish-l at lineu.icb.usp.br
http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l

 

 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110928/72be5d2c/attachment-0001.htm>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: not available
Type: image/gif
Size: 26494 bytes
Desc: image001.gif
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110928/72be5d2c/attachment-0001.gif>


More information about the Leish-l mailing list